HUTCHMED (China) (HMDCF) Other Non-Current Assets (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Other Non-Current Assets came in at $34.2 million in Q2 2026, down 15.83% year-over-year from $40.6 million in Q2 2025, and down 12.08% quarter-over-quarter from $38.9 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Other Non-Current Assets (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Other Non-Current Assets for 12 consecutive years, with $34.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non-Current Assets fell 15.83% year-over-year to $34.2 million in Q2 2026; TTM through Jun 2026 was $34.2 million, a 15.83% decrease from a year earlier, with the FY2025 full-year figure at $38.9 million, up 212.51% from the prior year.
- Other Non-Current Assets was $34.2 million for Q2 2026 at HUTCHMED (China), down from $38.9 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $45.0 million in Q2 2022 and troughed at $12.4 million in Q4 2024.
- A 5-year average of $36.0 million and a median of $39.2 million in 2023 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 212.51% in 2025 and declined 15.83% in 2026, its largest moves.
- Over 5 years, Other Non-Current Assets stood at $39.8 million in 2022, then decreased by 0.72% to $39.5 million in 2023, then slumped by 68.54% to $12.4 million in 2024, then jumped by 212.51% to $38.9 million in 2025, then dropped by 12.08% to $34.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $34.2 million (Q2 2026), $38.9 million (Q4 2025), and $40.6 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | 29.59 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 34.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.19 Mn |
| Dec 31, 2025 | 38.89 Mn |
| Jun 30, 2025 | 40.62 Mn |
| Dec 31, 2024 | 12.44 Mn |
| Jun 30, 2024 | 37.27 Mn |
| Jun 30, 2023 | 39.55 Mn |
| Dec 31, 2022 | 39.83 Mn |
| Jun 30, 2022 | 45.04 Mn |
| Dec 31, 2021 | 21.55 Mn |
| Jun 30, 2021 | 24.71 Mn |
| Mar 31, 2021 | 26.97 Mn |
| Dec 31, 2020 | 20.17 Mn |
| Jun 30, 2020 | 6.64 Mn |
| Dec 31, 2019 | 5.78 Mn |
| Sep 30, 2019 | 6.58 Mn |
| Jun 30, 2019 | 6.77 Mn |
| Mar 31, 2019 | 6.77 Mn |
| Dec 31, 2018 | 292,000.00 |
| Jun 30, 2018 | 6.58 Mn |
| Dec 31, 2017 | 123,000.00 |